Trials / Completed
CompletedNCT03235219
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 1b study is to assess the safety and tolerability of JNJ-64565111 in adult men and women (of non-child bearing potential) with Type 2 Diabetes Mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64565111 | Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22. |
| DRUG | Placebo | Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22. |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2018-02-19
- Completion
- 2018-02-19
- First posted
- 2017-08-01
- Last updated
- 2025-04-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03235219. Inclusion in this directory is not an endorsement.